NEW YORK (GenomeWeb) – Owlstone Medical said today it has signed a service agreement with AstraZeneca to study breath-based biomarkers for asthma and COPD.

Under the terms of the agreement, Owlstone will give AstraZeneca access to its Breath Biopsy Services to help the pharmaceutical company identify breath-based biomarkers as well as classification algorithms for the conditions, with the aim of identifying disease phenotypes and the best treatments for those phenotypes.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
15
Sponsored by
Swift Biosciences

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.